Trial Parameters
Condition COVID
Sponsor Tanta University
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 160
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2020-05-08
Completion 2030-12-01
All Conditions
Interventions
Nitazoxanide
Brief Summary
Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.
Eligibility Criteria
Inclusion Criteria: * Patients with COVID-19 infection Exclusion Criteria: * Allergy or contraindication to the drugs.